[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Tango Therapeutics Inc (TNGX)

Tango Therapeutics Inc (TNGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,768,434
  • Shares Outstanding, K 168,610
  • Annual Sales, $ 62,380 K
  • Annual Income, $ -101,590 K
  • EBIT $ -136 M
  • EBITDA $ -137 M
  • 60-Month Beta 1.12
  • Price/Sales 61.73
  • Price/Cash Flow N/A
  • Price/Book 3.30

Options Overview Details

View History
  • Implied Volatility 80.33% (+2.80%)
  • Historical Volatility 53.74%
  • IV Percentile 8%
  • IV Rank 9.58%
  • IV High 538.02% on 12/17/25
  • IV Low 31.85% on 08/26/26
  • Expected Move (DTE 16) 0.77 (3.42%)
  • Put/Call Vol Ratio 0.27
  • Today's Volume 144
  • Volume Avg (30-Day) 680
  • Put/Call OI Ratio 1.35
  • Today's Open Interest 13,690
  • Open Int (30-Day) 11,185
  • Expected Range 21.59 to 23.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.34
  • Number of Estimates 6
  • High Estimate $-0.31
  • Low Estimate $-0.41
  • Prior Year $0.13
  • Growth Rate Est. (year over year) -361.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.07 +1.27%
on 09/01/26
30.25 -26.12%
on 08/05/26
-4.83 (-17.77%)
since 07/31/26
3-Month
19.43 +15.04%
on 06/05/26
34.39 -35.01%
on 06/17/26
-0.75 (-3.25%)
since 06/01/26
52-Week
6.25 +257.60%
on 09/10/25
34.39 -35.01%
on 06/17/26
+15.64 (+233.08%)
since 08/29/25

Most Recent Stories

More News
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to...

TNGX : 22.35 (-2.15%)
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Announces Executive Chair Transition

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Announces Executive Chair Transition

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Appoints Robert Azelby to Board of Directors

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Appoints Robert Azelby to Board of Directors

BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of...

TNGX : 22.35 (-2.15%)
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

BOSTON, June 09, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (“Tango”) (Nasdaq: TNGX), a clinical-stage biotechnology company committed to...

TNGX : 22.35 (-2.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 23.91
2nd Resistance Point 23.48
1st Resistance Point 22.92
Last Price 22.35
1st Support Level 21.93
2nd Support Level 21.50
3rd Support Level 20.94

See More

52-Week High 34.39
Fibonacci 61.8% 23.64
Last Price 22.35
Fibonacci 50% 20.32
Fibonacci 38.2% 17.00
52-Week Low 6.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.